Authors' reply

Comment

. 2023 Dec;130(13):1698-1699.

doi: 10.1111/1471-0528.17649. Epub 2023 Sep 5.

Ann-Sophie Page^{1

2}, Jan Y Verbakel^{3

4}, Jan Deprest^{1

2}

Affiliations

¹ Department Obstetrics & Gynaecology, Pelvic Floor Unit, University Hospitals KU Leuven, Leuven, Belgium.
² Academic Department Development and Regeneration, Cluster Urogenital Surgery, KU Leuven, Leuven, Belgium.
³ Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
⁴ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Comment

Ann-Sophie Page et al. BJOG. 2023 Dec.

. 2023 Dec;130(13):1698-1699.

doi: 10.1111/1471-0528.17649. Epub 2023 Sep 5.

Ann-Sophie Page^{1

2}, Jan Y Verbakel^{3

4}, Jan Deprest^{1

2}

¹ Department Obstetrics & Gynaecology, Pelvic Floor Unit, University Hospitals KU Leuven, Leuven, Belgium.
² Academic Department Development and Regeneration, Cluster Urogenital Surgery, KU Leuven, Leuven, Belgium.
³ Department of Public Health and Primary Care, KU Leuven, Leuven, Belgium.
⁴ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

No abstract available

Comment on

Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial - Some crucial criticalities.
Salvatore S, Cardozo L, Ruffolo AF, Athanasiou S. Salvatore S, et al. BJOG. 2023 Dec;130(13):1697-1698. doi: 10.1111/1471-0528.17489. Epub 2023 Apr 11. BJOG. 2023. PMID: 37041659 No abstract available.

1. Salvatore S, Cardozo L, Ruffolo AF, Athanasiou S. Laser versus sham for genitourinary syndrome of menopause: A randomised controlled trial - Some crucial criticalities. BJOG. 2023. https://doi.org/10.1111/1471-0528.17489.
1. Mitchell CM, Reed SD, Diem S, Larson JC, Newton KM, Ensrud KE, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial. JAMA Intern Med. 2018;178:681-690.
1. Shobeiri SA, Kerkhof M, Minassian VA, Bazi T. IUGA committee opinion: laser-based vaginal devices for treatment of stress urinary incontinence, genitourinary syndrome of menopause, and vaginal laxity. Int Urogynecol J. 2019;30:371-376.
1. NICE. Transvaginal laser therapy for urogenital atrophy. Interventional procedures guidance. 2021.
1. FDA. FDA warns against use of energy-based devices to perform vaginal rejuvenation or vaginal cosmetic procedures: FDA safety communication. 2018 [cited 2018 Jul 30]. Available from: https://www.fda.gov/medical-devices/safety-communications/fda-warns-agai...